Analysts Are Bullish on These Healthcare Stocks: Syros Pharmaceuticals (SYRS), Motus Gi Holdings (MOTS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Syros Pharmaceuticals (SYRS – Research Report), Motus Gi Holdings (MOTS – Research Report) and TransCode Therapeutics (RNAZ – Research Report) with bullish sentiments.

Syros Pharmaceuticals (SYRS)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Syros Pharmaceuticals today and set a price target of $20.00. The company’s shares closed last Monday at $3.66, close to its 52-week low of $3.52.

According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -10.4% and a 35.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals.

Syros Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $30.75, which is a 686.4% upside from current levels. In a report released yesterday, Brookline Capital Markets also maintained a Buy rating on the stock with a $60.00 price target.

See the top stocks recommended by analysts >>

Motus Gi Holdings (MOTS)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Motus Gi Holdings, with a price target of $10.00. The company’s shares closed last Monday at $1.87, close to its 52-week low of $1.53.

According to TipRanks.com, Chen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -28.1% and a 24.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, EyePoint Pharmaceuticals, and Aslan Pharmaceuticals.

Currently, the analyst consensus on Motus Gi Holdings is a Moderate Buy with an average price target of $8.00, implying a 344.4% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $6.00 price target.

TransCode Therapeutics (RNAZ)

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on TransCode Therapeutics today and set a price target of $6.00. The company’s shares closed last Monday at $0.51, close to its 52-week low of $0.45.

According to TipRanks.com, Bodnar ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.8% and a 37.3% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, Context Therapeutics, and SQZ Biotechnologies.

TransCode Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SYRS:

• H.C. Wainwright Sticks to Its Buy Rating for Alimera (ALIM)
• CymaBay Therapeutics (CBAY) Gets a Buy from H.C. Wainwright
• H.C. Wainwright Sticks to Its Buy Rating for TScan Therapeutics (TCRX)
• H.C. Wainwright Reaffirms Their Buy Rating on Acumen Pharmaceuticals (ABOS)
• Wedbush Remains a Buy on Aerovate Therapeutics (AVTE)